News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) and Its Big Bet on Alzheimer's Drug



3/5/2012 7:42:15 AM

In the world of the pharma patent cliff, Eli Lilly & Co. (NYSE:LLY) stands in a particularly vulnerable spot. As the drugmaker awaits clinical trial results from a late-stage Alzheimer’s candidate, company leaders are faced with reports of decreasing revenue and more patent expirations. They are crossing their fingers that solanezumab, which most analysts lack confidence in, meets its benchmarks. Meanwhile, a competitor’s Alzheimer’s candidate is at the same point in the clinical trial process. Analysts suggest that success with solanezumab could make a secure future for Lilly in the Alzheimer’s treatment market. A failure, on the other hand, would set Lilly even further back in its battle against the patent cliff.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES